|
[1]LOK AS,MCMAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.
|
|
[2]European Association For The Study Of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[3]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(3):531-561.
|
|
[4]CHEN YP,LIANG XE,DAI L,et al.Improving transient elastography performance for detecting hepatitis B cirrhosis[J].Dig Liver Dis,2012,44(1):61-66.
|
|
[5]CHEN YP,LIANG XE,ZHANG Q,et al.Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B[J].J Gastroenterol Hepatol,2012,27(7):1219-1226.
|
|
[6]WHO Guidelines Approved by the Guidelines Review Committee.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:recommendations for a public health approach[M].Geneva:World Health Organization,2013.
|
|
[7]LIANG J,TANG YF,WU FS,et al.Entecavir versus lamivudine for the treatment of chronic hepatitis B:a systematic review[J].Pharmazie,2012,67(11):883-890.
|
|
[8]ZHAO P,LIU W,ZHAO J,et al.Comparison of the 48-week efficacy between entecavir and adefovir in HBe Ag-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B:a meta-analysis[J].Virol J,2011,8:75.
|
|
[9]MARCELLIN P,HEATHCOTE EJ,BUTI M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.
|
|
[10]PRICE H,DUNN D,PILLAY D,et al.Suppression of HBV by tenofovir in HBV/HIV coinfected patients:a systematic review and meta-analysis[J].PLo S One,2013,8(7):e68152.
|
|
[11]MURRAY KF,SZENBORN L,WYSOCKI J,et al.Randomized,placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B[J].Hepatology,2012,56(6):2018-2026.
|
|
[12]FUNG SK,CHAE HB,FONTANA RJ,et al.Virologic response and resistance to adefovir in patients with chronic hepatitis B[J].J Hepatol,2006,44(2):283-290.
|
|
[13]SARRI G,WESTBY M,BERMINGHAM S,et al.Diagnosis and management of chronic hepatitis B in children,young people,and adults:summary of NICE guidance[J].BMJ,2013,346:f3893.
|
|
[14]LOK AS,ZOULIM F,LOCARNINI S,et al.Antiviral drug-resistant HBV:standardization of nomenclature and assays and recommendations for management[J].Hepatology,2007,46(1):254-265.
|
|
[15]PALLIER C,CASTRA L,SOULIER A,et al.Dynamics of hepatitis B virus resistance to lamivudine[J].J Virol,2006,80(2):643-653.
|
|
[16]HUANG ZB,ZHAO SS,HUANG Y,et al.Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B:a systematic review and meta-analysis[J].Clin Ther,2013,35(12):1997-2006.
|
|
[17]LIM LG,AUNG MO,SEET BL,et al.Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance[J].World J Gastroenterol,2010,16(37):4691-4696.
|
|
[18]LIANG Y,JIANG J,SU M,et al.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy[J].Aliment Pharmacol Ther,2011,34(3):344-352.
|
DownLoad: